Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.

Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B.

J Thromb Haemost. 2010 Feb;8(2):351-9. doi: 10.1111/j.1538-7836.2009.03699.x. Epub 2009 Nov 23.

2.

Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.

Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hübl W, Wojta J, Huber K.

Thromb Haemost. 2011 Aug;106(2):230-9. doi: 10.1160/TH11-02-0077. Epub 2011 May 26.

PMID:
21614416
3.

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.

Am J Cardiol. 2009 Oct 15;104(8):1078-82. doi: 10.1016/j.amjcard.2009.06.007.

PMID:
19801028
4.

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.

J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.

5.

Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.

Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2010 Jan;103(1):151-9. doi: 10.1160/TH09-05-0284. Epub 2009 Oct 26.

PMID:
20062919
6.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008. Epub 2011 May 28.

PMID:
21621250
7.

Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.

von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A.

Blood Coagul Fibrinolysis. 2010 Jan;21(1):46-52. doi: 10.1097/MBC.0b013e328332dbd4.

PMID:
19823079
8.

The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.

Blindt R, Stellbrink K, de Taeye A, Müller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R.

Thromb Haemost. 2007 Dec;98(6):1329-34.

PMID:
18064332
9.

Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Haemost. 2009 Feb;101(2):333-9.

PMID:
19190818
10.

A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.

Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z, Widimsky P.

Catheter Cardiovasc Interv. 2010 Feb 1;75(2):158-66. doi: 10.1002/ccd.22248.

PMID:
19902490
11.

Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?

Cotton JM, Worrall AM, Hobson AR, Smallwood A, Amoah V, Dunmore S, Nevill AM, Raghuraman RP, Vickers J, Curzen N.

Cardiovasc Ther. 2010 Jun;28(3):139-46. doi: 10.1111/j.1755-5922.2010.00156.x. Epub 2010 Apr 19. Erratum in: Cardiovasc Ther. 2010 Aug;28(4):254. Rajendra, R [corrected to Raghuraman, R P].

PMID:
20406238
12.

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.

13.

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L.

J Thromb Haemost. 2007 Aug;5(8):1630-6. Epub 2007 May 7.

14.

The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.

Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B.

Thromb Res. 2009 Apr;123(6):874-80. doi: 10.1016/j.thromres.2008.11.005. Epub 2009 Jan 9.

PMID:
19135705
15.

Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.

JACC Cardiovasc Interv. 2010 Jun;3(6):648-56. doi: 10.1016/j.jcin.2010.03.003.

16.

Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.

Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.

Platelets. 2010;21(7):563-70. doi: 10.3109/09537104.2010.494742.

PMID:
20642320
17.

Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.

Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, Cattaneo M, Minuz P.

J Thromb Haemost. 2016 Feb;14(2):282-93. doi: 10.1111/jth.13197. Epub 2016 Jan 29.

PMID:
26576037
18.

[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].

Morel O, Viellard C, Faure A, Jesel L, Ohlmann P, Desprez D, Chauvin M, Roul G, Grunebaum L, Bareiss P.

Ann Cardiol Angeiol (Paris). 2007 Jan;56(1):21-9. French.

PMID:
17343035
19.

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.

Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.

J Thromb Haemost. 2010 Mar;8(3):482-8. doi: 10.1111/j.1538-7836.2009.03733.x. Epub 2009 Dec 21.

20.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A.

J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.

Supplemental Content

Support Center